Erlotinib 13C6 is a stable isotope-labeled form of erlotinib, which is an epidermal growth factor receptor (EGFR) inhibitor used primarily in the treatment of non-small cell lung cancer and pancreatic cancer. The designation "13C6" indicates that the compound contains six carbon atoms that are isotopically labeled with carbon-13, a stable isotope of carbon. This labeling is often utilized in pharmacokinetic studies to trace the compound's metabolism and distribution in biological systems. Erlotinib itself functions by blocking the ATP-binding site of the EGFR tyrosine kinase, thereby inhibiting downstream signaling pathways that promote cell proliferation and survival. The compound is typically administered orally and is known for its ability to penetrate the blood-brain barrier, making it effective for certain types of tumors. Its pharmacological profile includes a half-life that allows for once-daily dosing, and it is metabolized primarily by the liver. As with many targeted therapies, it may have specific side effects, including skin rash and gastrointestinal disturbances.

Erlotinib 13C6

1211107-68-4: Erlotinib 13C6 is a stable isotope-labeled form of erlotinib, which is an epidermal growth factor receptor (EGFR) inhibitor used primarily in the treatment of non-small cell lung cancer and pancreatic cancer. The designation "13C6" indicates that the compound contains six carbon atoms that are isotopically labeled with carbon-13, a stable isotope of carbon. This labeling is often utilized in pharmacokinetic studies to trace the compound's metabolism and distribution in biological systems. Erlotinib itself functions by blocking the ATP-binding site of the EGFR tyrosine kinase, thereby inhibiting downstream signaling pathways that promote cell proliferation and survival. The compound is typically administered orally and is known for its ability to penetrate the blood-brain barrier, making it effective for certain types of tumors. Its pharmacological profile includes a half-life that allows for once-daily dosing, and it is metabolized primarily by the liver. As with many targeted therapies, it may have specific side effects, including skin rash and gastrointestinal disturbances.

<p>Erlotinib-13C6 (CP-358774-13C6), a 13C-labeled direct EGFR inhibitor, IC50: 2 nM.</p>

CAS 1211107-68-4

Erlotinib 13C6

Erlotinib-13C6

Ref: TM-T35915